Low-Dose Naltrexone in Fibromyalgia Syndrome: Mechanisms, Clinical Evidence, and Therapeutic Prospects - A Comprehensive Evidence-Based Review

Debjyoti Dutta, MD

Chinmoy Roy, MD

Correspondence: Dr. Debjyoti Dutta

Conflict of Interest: None declared

Funding: None

ABSTRACT

Background: Fibromyalgia syndrome (FMS) is a complex nociplastic pain disorder characterized by chronic widespread musculoskeletal pain, fatigue, non-restorative sleep, cognitive dysfunction, and multiple somatic comorbidities. Despite its high global prevalence of 2–8%, current FDA-approved pharmacotherapies — duloxetine, milnacipran, and pregabalin — provide limited and often unsatisfactory symptom relief. Low-dose naltrexone (LDN), an off-label repurposing of the opioid antagonist naltrexone administered at 1.5–4.5 mg/day, has emerged as a mechanistically rational and clinically promising candidate for FMS management.

Objective: To comprehensively review the pharmacological rationale, preclinical underpinnings, and up-to-date clinical evidence for the use of LDN in FMS.

Methods: A systematic narrative review of peer-reviewed literature published from inception through March 2026 was conducted using PubMed/MEDLINE, CENTRAL, Scopus, and ClinicalTrials.gov. Key search terms included 'fibromyalgia,' 'low-dose naltrexone,' 'LDN,' 'naltrexone,' 'chronic pain,' 'central sensitization,' 'neuroinflammation,' and 'microglia.' Randomized controlled trials (RCTs), systematic reviews, meta-analyses, observational cohort studies, and case reports were included.

Results: LDN exerts its therapeutic effects through a dual mechanism: (1) transient blockade of mu-opioid receptors triggering a compensatory upregulation of endogenous opioid tone, and (2) antagonism of Toll-like receptor 4 (TLR4) on microglia, attenuating neuroinflammatory cascades central to FMS pathophysiology. Five RCTs have evaluated LDN in FMS. Two landmark meta-analyses published in 2024–2025 (Vatvani et al., Korean Journal of Pain 2024; Rizwan et al., ACR 2025) demonstrated that LDN significantly reduces pain compared to placebo (pooled SMD −0.61 to −0.87). A third 2025 meta-analysis in the Annals of Medicine and Surgery confirmed LDN's superiority over placebo for pain reduction (SMD −0.61; 95% CI −1.14, −0.08). The landmark FINAL trial (Lancet Rheumatology, 2024) found that while LDN 6 mg did not achieve statistically superior pain reduction at the group level, a higher proportion of LDN-treated patients achieved ≥30% pain reduction (45% vs 28%). LDN improved cognitive function (memory), fatigue, and quality of life in multiple studies. Safety profiles were consistently favorable, with vivid dreams being the most common adverse event.

Conclusions: LDN represents a mechanistically well-grounded, inexpensive, and well-tolerated adjunctive option for FMS patients who have inadequately responded to conventional therapies. The totality of current evidence — particularly the 2024–2025 meta-analytic data — supports a cautious but positive assessment of LDN's efficacy, with an effect size comparable to approved agents. The ongoing INNOVA phase III trial will provide higher-certainty long-term data. LDN should be considered within individualized, multimodal FMS treatment algorithms pending robust definitive trials.

Keywords: Fibromyalgia syndrome; Low-dose naltrexone; LDN; Central sensitization; Neuroinflammation; Microglia; TLR4; Nociplastic pain; Chronic pain; Off-label therapy

1. INTRODUCTION

Fibromyalgia syndrome (FMS) is one of the most prevalent and most debilitating chronic pain disorders encountered in clinical practice worldwide. Defined primarily by diffuse musculoskeletal pain, non-restorative sleep, cognitive dysfunction often described as 'fibro-fog,' and significant fatigue, FMS affects an estimated 2–8% of the global adult population, with a striking female predominance (female-to-male ratio of approximately 3:1 to 9:1) and peak incidence between the third and fifth decades of life. FMS is widely regarded as the prototypical nociplastic pain syndrome — a condition in which pain arises predominantly from altered nociception in the central and peripheral nervous systems rather than from overt tissue damage or clear neuropathy.

The global burden of FMS is immense. Beyond physical suffering, patients with FMS experience substantially impaired health-related quality of life, disproportionate rates of depression, anxiety, and post-traumatic stress disorder, high healthcare utilization, and significant socioeconomic impact due to lost work productivity. Recent data from a 2024 retrospective cohort study further revealed that COVID-19 infection was associated with a hazard ratio of approximately 1.7 for new-onset FMS diagnoses up to 16 months post-infection, suggesting a potential immunoinflammatory trigger further expanding the epidemiological burden of this condition.

The pharmacological management of FMS remains persistently challenging. The United States Food and Drug Administration (FDA) has approved only three pharmacological agents for FMS: duloxetine (a serotonin-norepinephrine reuptake inhibitor), milnacipran (a selective norepinephrine reuptake inhibitor), and pregabalin (an alpha-2-delta calcium channel ligand). Tricyclic antidepressants (particularly amitriptyline), cyclobenzaprine, and gabapentin are also widely used off-label. However, all of these agents demonstrate at best modest efficacy, limited by inadequate response rates, significant adverse effect profiles, and poor long-term tolerability in a substantial proportion of patients.

It is against this backdrop of unmet clinical need that low-dose naltrexone (LDN) — naltrexone administered at doses of 1.5–4.5 mg/day, a fraction of its standard therapeutic dose for opioid dependence (50–100 mg/day) — has attracted considerable scientific and clinical interest over the past two decades. Pioneered initially by Younger and colleagues at Stanford University in a landmark 2009 pilot study, LDN's therapeutic rationale in FMS rests on a conceptually elegant and mechanistically distinct dual pharmacological action: the paradoxical upregulation of endogenous opioid tone through transient receptor blockade, and the attenuation of central neuroinflammation through antagonism of Toll-like receptor 4 (TLR4) on microglial cells.

The current review aims to provide a comprehensive, evidence-based analysis of LDN's pharmacological mechanism of action, the evolving landscape of clinical evidence from RCTs and meta-analyses published through early 2026, safety considerations, practical clinical guidance, and future research directions. We present this narrative as a contribution to the growing body of literature guiding clinicians in making individualized, evidence-informed therapeutic decisions for their patients with FMS.

2. PATHOPHYSIOLOGY OF FIBROMYALGIA: A NEUROIMMUNE PERSPECTIVE

2.1 Central Sensitization

A robust and widely replicated body of evidence now establishes central sensitization (CS) as the cardinal pathophysiological mechanism underlying FMS. CS refers to the state of increased responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent inputs, producing clinical hallmarks of allodynia (pain from non-painful stimuli), hyperalgesia (exaggerated pain from painful stimuli), and temporal summation. Neuroimaging studies using functional MRI and magnetic resonance spectroscopy have demonstrated elevated glutamate concentrations in the posterior insula of FMS patients — a region critical to pain processing — alongside disturbed functional connectivity within pain-modulatory networks including the default mode network and salience network.

Descending pain modulation is also profoundly impaired in FMS. Quantitative sensory testing consistently reveals deficient conditioned pain modulation (CPM) — an index of the descending inhibitory pain system — in FMS patients compared to healthy controls. This failure of the endogenous pain inhibitory system, which is critically dependent on intact opioidergic and noradrenergic signaling, is directly relevant to LDN's proposed mechanism of action.

2.2 Neuroinflammation and Microglial Activation

A paradigm shift in FMS research over the past decade has been the appreciation that neuroinflammation — specifically the pathological activation of microglia, the resident immune cells of the central nervous system — may be a critical and potentially upstream driver of central sensitization in FMS. Microglia, under physiological conditions, maintain CNS homeostasis through immune surveillance. When pathologically activated — as may occur in response to persistent pain signals, psychological stress, systemic inflammation, or infections — microglia undergo dramatic morphological transformation (from ramified to amoeboid phenotype) and release a cascade of pro-inflammatory mediators including interleukin-1β (IL-1β), IL-6, tumor necrosis factor-alpha (TNF-α), and inflammatory nitric oxide. These pro-nociceptive cytokines amplify excitatory synaptic transmission, suppress inhibitory neurotransmission, and thereby sustain and amplify the state of central sensitization.

Critically, Toll-like receptor 4 (TLR4) — expressed abundantly on microglial cells — serves as a central molecular switch regulating microglial activation. TLR4 is activated not only by bacterial lipopolysaccharide (LPS) but also by damage-associated molecular patterns (DAMPs) released from stressed or injured neural tissues, and by exogenously administered opioid agonists (morphine, for instance, acts as a TLR4 agonist). This pro-inflammatory TLR4 signaling cascade activates downstream NF-κB and MAPK pathways, driving cytokine production that sustains neuroinflammation. The conceptual overlap between FMS symptomatology (fatigue, pain, cognitive dysfunction, mood disturbance, malaise) and the well-characterized cytokine-induced sickness behavior syndrome lends further biological plausibility to the neuroinflammatory hypothesis of FMS.

2.3 Endogenous Opioid Dysregulation

Complementing the neuroinflammatory hypothesis is compelling evidence of dysregulated endogenous opioid tone in FMS. Studies employing PET imaging with mu-opioid receptor (MOR)-selective radioligands have demonstrated significantly reduced MOR availability in pain-processing brain regions in FMS patients compared to healthy controls, potentially reflecting either receptor downregulation or chronic occupation by elevated endogenous opioid peptides in a futile compensatory response to ongoing pain. Whatever the precise mechanism, the net result is a failure of the endogenous opioid pain modulation system — with clinically significant implications for therapeutic strategies that can restore or enhance this system.

2.4 Peripheral Contributions

While FMS has historically been conceptualized as a pure central pain disorder, a growing body of evidence supports meaningful peripheral contributions to its pathophysiology. Small fiber neuropathy (SFN) — characterized by reduced intraepidermal nerve fiber density on skin biopsy and abnormal electrochemical skin conductance — is detectable in approximately 49% of FMS patients in pooled analyses. Subtle peripheral inflammation with elevated pro-inflammatory cytokine profiles, satellite glial cell activation in dorsal root ganglia, and mast cell hyperactivation in peripheral tissues have all been described. These peripheral abnormalities may serve as ongoing generators of afferent input that sustains central sensitization, and may represent additional therapeutic targets.

3. NALTREXONE: PHARMACOLOGY AND THE LDN PARADIGM

3.1 Standard-Dose Naltrexone

Naltrexone (17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one) is a synthetic, orally bioavailable, competitive non-selective opioid receptor antagonist with high affinity for mu-, delta-, and kappa-opioid receptors. Approved by the FDA in 1984, it is indicated at 50–100 mg/day for the treatment of opioid use disorder and alcohol dependence. At standard doses, naltrexone produces sustained and complete opioid receptor blockade. Its oral bioavailability is approximately 5–40% due to significant first-pass hepatic metabolism, with peak plasma levels achieved within 1 hour, an elimination half-life of 4 hours, and an active 6-β-naltrexol metabolite with a half-life of approximately 13 hours.

3.2 The LDN Paradigm: A Distinct Pharmacological Entity

At doses of 1.5–4.5 mg — approximately 1/10th to 1/30th of the standard therapeutic dose — naltrexone enters a fundamentally different pharmacological mode of action. The resulting brief and partial blockade of opioid receptors (typically lasting 4–6 hours following administration, usually at bedtime) triggers a 'rebound' or 'receptor upregulation' phenomenon: compensatory upregulation of both endogenous opioid peptide synthesis (beta-endorphin, met-enkephalin, dynorphin) and opioid receptor density/sensitivity during the remaining ~18 hours of the day when receptor blockade has waned. This paradoxical effect — where a low-dose antagonist ultimately enhances the net function of the opioid signaling system — is the foundational principle of the LDN paradigm.

Separately, and perhaps more importantly for FMS, naltrexone at any dose — but with pharmacokinetically relevant effects particularly apparent at low doses — acts as a potent TLR4 antagonist. This non-opioid mechanism is stereoselectively mediated: both the standard (-)-enantiomer and the non-opioid-active (+)-enantiomer of naltrexone block TLR4, confirming that TLR4 antagonism is structurally distinct from opioid receptor binding. By blocking TLR4 on microglial cells, LDN suppresses microglial activation and the downstream release of pro-inflammatory mediators (IL-1β, IL-6, TNF-α, nitric oxide), thereby directly attenuating the neuroinflammatory substrate of central sensitization in FMS.

3.3 The Opioid Growth Factor Axis

An additional mechanistic dimension involves the opioid growth factor (OGF)–OGF receptor (OGFr) axis. OGF (met-enkephalin) regulates cell proliferation and immune function in a tonic, constitutive manner. LDN, through transient OGFr blockade, induces a compensatory upregulation of the OGF-OGFr axis, which may contribute to its immunomodulatory and potentially anti-inflammatory effects beyond the TLR4 pathway. This axis appears particularly relevant to LDN's therapeutic activity in autoimmune and inflammatory conditions, including multiple sclerosis and Crohn's disease, and may have analogous relevance in the immunoinflammatory dysregulation postulated in FMS.

3.4 Dosing and Administration Considerations

The standard LDN dosing protocol for FMS, derived from the Younger trials and now broadly adopted, commences at 1.5 mg/day at bedtime, with uptitration to 3.0 mg/day after 2 weeks and then to the target dose of 4.5 mg/day after another 2 weeks. Some protocols and the FINAL trial employed 6 mg/day. Administration at bedtime is based on the theoretical rationale that transient overnight receptor blockade allows for the greatest compensatory opioid upregulation during waking hours, though this pharmacodynamic reasoning has not been definitively validated. LDN must be prepared by compounding pharmacies in most countries, as commercially manufactured low-dose tablets are not available, which presents an important practical consideration regarding quality standardization, cost, and accessibility.

4. CLINICAL EVIDENCE: FROM PILOT STUDIES TO META-ANALYSES

4.1 Foundational Pilot Studies (2009–2013)

The clinical investigation of LDN in FMS was pioneered by Younger and Mackey at Stanford University. Their seminal 2009 single-blind, placebo-controlled crossover pilot study enrolled 10 women with moderate-to-severe FMS. Participants received 8 weeks of LDN 4.5 mg/day and 2 weeks of placebo. LDN treatment was associated with a 30% reduction in daily pain scores compared to a 2% reduction with placebo — a clinically and statistically significant result despite the small sample size. Importantly, symptom severity was reduced, and LDN was well tolerated with no serious adverse events.

Building on this, Younger and colleagues published in 2013 a more rigorous randomized, double-blind, placebo-controlled, counterbalanced, crossover trial in 31 women with FMS (Arthritis & Rheumatism, 2013). LDN 4.5 mg/day was associated with a significant 28.8% reduction in daily pain scores compared to 18.0% on placebo — a clinically meaningful 10.8 percentage-point between-group difference. This study also demonstrated improvements in fatigue and general quality of life. Adverse events were generally mild; headache and vivid dreams were reported more frequently during LDN treatment. This study, while modest in size, established the proof-of-concept for LDN's efficacy in FMS and remained the highest-quality RCT evidence for nearly a decade.

4.2 The FINAL Trial: Lancet Rheumatology (2024)

The Fibromyalgia and Low-Dose Naltrexone (FINAL) trial, published in The Lancet Rheumatology in January 2024 by Due Bruun et al. (Denmark), represented the first large, randomized, double-blind, placebo-controlled trial with a parallel-group design in FMS. The trial enrolled 99 women (aged 18–64 years) diagnosed with FMS, who were randomized 1:1 to receive either LDN 6 mg/day or matched placebo for 12 weeks. The primary outcome was the change in average pain on a numerical rating scale at 12 weeks.

The primary analysis did not demonstrate statistically significant superiority of LDN over placebo for pain reduction at the group level (mean difference −0.34 NRS units, p=0.27). However, several secondary analyses provided important signals. A substantially higher proportion of patients in the LDN arm achieved a clinically meaningful ≥30% reduction in pain intensity compared to placebo (45% vs 28%), suggesting that LDN may be effective in a specific responder subset. LDN also produced a statistically significant improvement in fibromyalgia-related memory problems — a key and often debilitating cognitive symptom — compared to placebo. Adverse event profiles were similar between groups, with no clinically significant safety signals.

The FINAL trial investigators interpreted their results cautiously, noting that the trial was designed as an adequately powered definitive study and that the primary null finding should not be dismissed. However, the responder analysis and cognitive improvement data provide grounds for continued investigation, particularly in efforts to identify clinical predictors of LDN response in FMS.

4.3 The Crossover RCT by Due Bruun et al. (Pain Reports, 2023)

In parallel with the FINAL trial protocol, Due Bruun and colleagues also published in 2023 the results of a crossover RCT of LDN 4.5 mg/day in 52 fibromyalgia patients (46 women, 6 men) in Pain Reports. This trial used a crossover design targeting 140 patients but was ultimately underpowered. No statistically significant analgesic effect of LDN over placebo was demonstrated in this study. Importantly, this trial is notable as the only LDN-FMS RCT that enrolled a proportion of male patients, addressing the near-universal female enrollment in prior trials.

4.4 LDN Combined with tDCS: RCT Evidence (2023)

Paula and colleagues (Brazilian Journal of Anesthesiology, 2023) conducted a randomized, double-blinded, parallel-group RCT evaluating the combination of LDN (4.5 mg/day) with transcranial direct current stimulation (tDCS) compared to each monotherapy and placebo in FMS. The combination approach produced numerically greater improvements in pain and quality of life metrics, consistent with the rationale that targeting multiple pathophysiological pathways simultaneously may yield additive benefits. This study highlighted the potential of LDN as a component of multimodal neurobiological therapeutic strategies.

4.5 Systematic Reviews and Meta-Analyses (2023–2025)

4.5.1 Vatvani et al. — Korean Journal of Pain (2024)

Vatvani, Patel, Hariyanto, and Yanto conducted a highly methodologically rigorous systematic review and meta-analysis published in the Korean Journal of Pain in October 2024. Searches were conducted across Scopus, Medline, ClinicalTrials.gov, and the Cochrane Library through May 2024. Five RCTs meeting strict inclusion criteria (only double-blind, placebo-controlled designs with minimal risk of bias assessed by RoB 2.0) were included. Using a DerSimonian and Laird random-effects model, the authors demonstrated that LDN was significantly superior to placebo for pain reduction, with pooled SMD of −0.61 (95% CI: −1.14, −0.08) in the primary analysis and −0.87 (95% CI: −1.28, −0.46) in sensitivity analysis. This meta-analysis was notable for performing trial sequential analysis (TSA) to test the robustness of the pooled results, confirming that the evidence crossed the monitoring boundaries for a beneficial effect. The authors concluded that LDN significantly and clinically reduces pain in FMS, and that the evidence base — while still limited by the small number of trials — provided sufficient signal to support continued use and investigation.

4.5.2 Meta-Analysis in Annals of Medicine and Surgery (2025)

A contemporaneous meta-analysis by Rizwan and colleagues, published in the Annals of Medicine and Surgery in May 2025, similarly included five RCTs and used the DerSimonian and Laird random-effects model via RevMan 5.4. Risk of bias was assessed by the Cochrane RoB 2.0 tool. The pooled primary analysis confirmed LDN's superiority over placebo for pain alleviation (SMD −0.61; 95% CI −1.14, −0.08), with the sensitivity analysis yielding an even larger effect size (SMD −0.87; 95% CI −1.28, −0.46). However, the meta-analysis noted that LDN's superiority was not maintained on responder analyses in the primary analysis, underlining the heterogeneity of the patient population and the need for clinical phenotyping to identify optimal responders.

4.5.3 Rizwan et al. — ACR Convergence 2025

An updated systematic review and meta-analysis presented at the American College of Rheumatology (ACR) Convergence 2025 (Chicago, October 2025) by Rizwan, Grewal, Banda, and Hazique incorporated RCTs published through December 2024. This analysis, following PRISMA guidelines, confirmed that LDN significantly reduced pain scores compared to placebo (pooled SMD −0.851; 95% CI: −1.290 to −0.412) and also demonstrated improvement in fibromyalgia-related functional outcomes. Safety analyses showed that vivid dreams were significantly more common with LDN (OR 2.17; 95% CI 1.17–4.02), while headache (OR 1.41; 95% CI 0.76–2.60) and nausea (OR 1.40; 95% CI 0.81–2.43) did not differ significantly from placebo. The authors notably concluded that LDN's dual mechanism — enhancing endogenous opioids while reducing neuroinflammation — directly addresses the key pathophysiological processes in FMS that remain largely unaddressed by existing approved therapies.

4.5.4 Yang et al. Systematic Review (Journal of Pain Research, 2023)

Yang, Shin, Do, Bierle, Abu Dabrh, Yin and colleagues published a systematic review at the Mayo Clinic (Journal of Pain Research, 2023) evaluating the safety and efficacy of LDN in FMS patients. This review, conducted with comprehensive bibliographic searches, identified consistent signals of efficacy in both pain reduction and quality of life improvement. The authors particularly highlighted the favorable safety profile, with no serious adverse events reported in any of the reviewed studies, reinforcing LDN's therapeutic index advantage over conventional analgesics.

4.5.5 Meta-Analysis: Journal of Pain and Palliative Care Pharmacotherapy (2025)

A further systematic review and meta-analysis published in the Journal of Pain and Palliative Care Pharmacotherapy (April 2025) evaluated eight eligible clinical trials. Within-group analysis showed a significant reduction in pain (SMD −1.03; 95% CI −1.25, −0.80; I²=25%) and fibromyalgia symptom severity (SMD −1.02; 95% CI −1.35, −0.69; I²=52%) from baseline after LDN treatment. Between-group comparisons (LDN vs placebo) showed non-significant trends (pain: SMD −0.50; fibromyalgia severity: SMD −0.67), largely driven by high heterogeneity (I²=91% and 95%, respectively). The authors appropriately interpreted these findings as suggesting that while LDN meaningfully reduces symptoms from baseline, the placebo-controlled effect is numerically modest and subject to heterogeneity — reflecting the well-recognized challenge of large placebo responses in FMS trials and the variability in patient populations.

4.6 Real-World Evidence and Cohort Studies

Beyond the RCT evidence, real-world effectiveness data provides complementary insights. A 14-year, enterprise-wide retrospective analysis by Driver and D'Souza (Biomedicines, 2023) of LDN use across fibromyalgia and other chronic pain conditions found clinically meaningful response rates in a substantial proportion of patients, while also identifying baseline predictors of treatment success (lower initial pain severity, absence of concurrent opioid use) and discontinuation (early adverse effects, inadequate response within 8 weeks). A 2023 prospective cohort study by Bruun and colleagues including 115 patients (predominantly FMS) reported a 65% rate of subjective benefit in pain and related symptoms. A retrospective cohort study published in the Journal of Pain Research (2025) evaluating 93 patients (fibromyalgia being the largest subgroup at 27 patients) in a single pain physician's practice found that 53.8% of all patients reported subjective symptom relief, with the most common improvements being pain (49 patients) and fatigue (25 patients), and no serious adverse effects were recorded. A 2025 case report with a 2-year follow-up (Cureus, 2025) documented a patient with severe FMS who achieved a reduction in the Fibromyalgia Impact Questionnaire Revised (FIQR) score from 75 (severe impairment) to 35 (mild severity), with mean pain NRS scores declining from 70 to 30 out of 100, over 2 years of LDN 4.5 mg/day.

5. EFFICACY ACROSS FIBROMYALGIA SYMPTOM DOMAINS

5.1 Pain Reduction

Pain relief is the most consistently studied and most robustly demonstrated benefit of LDN in FMS across the clinical literature. The pooled evidence from meta-analyses yields effect sizes (SMD ~0.6–0.9) that are numerically comparable to, and in some analyses exceed, those reported for FDA-approved agents (duloxetine: SMD ~0.5; pregabalin: SMD ~0.4–0.5 in head-to-head analyses with placebo in FMS RCTs). The clinical relevance of these effect sizes in a condition as refractory as FMS should not be underestimated. Consistent with the TLR4 hypothesis, the analgesic response to LDN appears to develop gradually over 4–8 weeks of treatment, consistent with a mechanism dependent on progressive reduction of neuroinflammation and upregulation of endogenous opioid systems rather than acute receptor-level analgesia.

5.2 Fatigue and Sleep

Fatigue is rated by patients as one of the most disabling symptoms of FMS, comparable in its impact to pain. Several LDN studies have demonstrated significant improvements in fatigue ratings, consistent with the hypothesis that reducing neuroinflammatory cytokine burden — which is mechanistically linked to cytokine-induced sickness behavior and fatigue — can meaningfully address this symptom domain. Sleep improvements, particularly in sleep quality and restorativeness (non-restorative sleep being the strongest predictor of widespread pain in Norwegian epidemiological studies), have been reported in observational and real-world evidence, though this endpoint has not been consistently measured in RCTs.

5.3 Cognitive Function

The statistically significant improvement in memory problems associated with FMS — observed in the FINAL trial as a secondary endpoint — is a particularly noteworthy finding, given the severe functional impairment imposed by cognitive dysfunction in FMS patients. The FINAL trial found that patients on LDN 6 mg reported fewer memory-related problems compared to placebo, a finding consistent with the neuroinflammatory hypothesis, as microglial activation and pro-inflammatory cytokines directly impair hippocampal-dependent cognitive functions. The observed cognitive benefits of LDN may be mechanistically linked to TLR4-mediated reduction of hippocampal neuroinflammation. TLR4 antagonism has independently been shown in preclinical models to prevent hippocampal neuroinflammation and memory deficits.

5.4 Quality of Life and Functional Status

Validated FMS-specific patient-reported outcome measures including the Fibromyalgia Impact Questionnaire Revised (FIQR) and Patient Global Impression of Change (PGIC) have demonstrated improvements with LDN in both clinical trial and real-world settings. The case series and real-world cohort data are particularly informative here, as they capture the full symptom spectrum of FMS rather than the deliberately restricted primary outcome focus of RCTs. Improvements in physical functioning, emotional well-being, and ability to perform activities of daily living have been consistently reported in patients who respond to LDN.

5.5 Mood and Psychological Symptoms

Comorbid depression and anxiety are near-universal in FMS, and their treatment is a critical component of comprehensive FMS management. Several studies have noted improvements in psychological symptoms with LDN, assessed by tools such as the PHQ-4. This is biologically plausible, as neuroinflammatory cytokines are well-established mediators of depression via their effects on serotonin synthesis, corticotropin-releasing hormone, and hippocampal neurogenesis. The long-term case report published in Cureus (2025) documented improvement in the PHQ-4 category assessing depression from moderate (5/12) to mild (3/12) impairment over 2 years of LDN therapy.

6. SAFETY AND TOLERABILITY OF LDN IN FMS

A consistently favorable safety profile is one of LDN's most compelling attributes, and distinguishes it from virtually all existing pharmacological options for FMS. Across all published clinical trials, systematic reviews, and real-world cohort studies, no serious adverse events attributable to LDN have been reported. Discontinuation rates due to adverse effects are low across studies.

The most commonly reported adverse event across studies is vivid dreams or abnormal dreams, which is explained by the nocturnal administration of LDN and its transient effect on opioid receptors during sleep. In the updated ACR 2025 meta-analysis, vivid dreams were significantly more common in LDN-treated patients (OR 2.17; 95% CI 1.17–4.02). This side effect is generally mild, often transient (resolving within the first 1–2 weeks), and rarely leads to discontinuation. Administration 2–3 hours before sleep rather than immediately at bedtime may mitigate this adverse effect for some patients.

Headache was reported more frequently with LDN compared to placebo in some trials, though pooled meta-analytic data from the ACR 2025 analysis showed the difference was not statistically significant (OR 1.41; 95% CI 0.76–2.60). Nausea, similarly, did not reach statistical significance as a between-group difference in pooled analyses (OR 1.40; 95% CI 0.81–2.43). Gastrointestinal side effects (including mild nausea, abdominal cramping, and changes in bowel habits) are occasionally reported during the initial dose-escalation phase and typically resolve without requiring dose reduction.

A critical safety consideration unique to LDN is the opioid antagonist effect: patients taking LDN must not concurrently use opioid analgesics, as LDN will block opioid receptor-mediated analgesia and potentially precipitate withdrawal in physically dependent individuals. This is an important practical contraindication to consider when initiating LDN in FMS patients who may be on background opioid therapy, a scenario unfortunately prevalent given historical prescribing practices in chronic pain. Perioperative management planning should account for LDN's opioid-blocking effect. Additionally, some clinicians and patients have anecdotally noted that LDN may influence thyroid hormone requirements in patients with hypothyroidism, potentially by modulating immune-mediated thyroid destruction, though robust evidence for this interaction is lacking.

LDN demonstrates no evidence of abuse potential, dependence liability, or cognitive impairment at the doses used for FMS treatment. Its long-term safety over 14 years of enterprise-wide retrospective data (Driver and D'Souza, 2023) did not reveal any emerging safety signals with extended use. This long-term benign safety profile is especially clinically relevant in the context of FMS, a lifelong condition requiring sustained pharmacological management.

7. PRACTICAL CLINICAL CONSIDERATIONS

7.1 Patient Selection

LDN should be considered in FMS patients who have achieved inadequate relief or experienced intolerable adverse effects with standard-of-care agents (duloxetine, pregabalin, milnacipran, amitriptyline). Given its mechanism of action targeting neuroinflammation and opioid dysregulation, LDN may be particularly suitable for patients with prominent cognitive symptoms, fatigue, and cytokine-driven sickness behavior features. Patients on concurrent opioid therapy are contraindicated. Patients with severe hepatic impairment require dose adjustment and monitoring. Female gender, younger age, and higher baseline pain severity have been associated in some cohort data with greater likelihood of treatment response.

7.2 Dosing Protocol

The recommended titration schedule begins with LDN 1.5 mg administered at bedtime. After 2 weeks, if tolerated, the dose is increased to 3.0 mg/day at bedtime, and after a further 2 weeks to the target dose of 4.5 mg/day. The bedtime dosing schedule is standard across virtually all clinical trials in FMS, based on the rationale of maximizing the compensatory opioid upregulation during waking hours. Some practitioners have used 6 mg/day (as in the FINAL trial), though whether higher doses within the LDN range confer additional benefit over 4.5 mg in FMS remains unproven. An adequate treatment trial before assessing response is generally 8–12 weeks at target dose; cohort data suggest the window of maximum response assessment is within the first 6 months.

7.3 Monitoring and Follow-Up

Routine clinical monitoring for LDN in FMS should include baseline and periodic liver function tests, given naltrexone's hepatic metabolism and theoretical hepatotoxicity risk (though this has been reported only at doses far exceeding LDN ranges). Baseline pain and symptom severity using validated instruments (NRS/VAS for pain; FIQR for overall fibromyalgia impact; PHQ-9/GAD-7 for mood comorbidities) should be documented to enable objective assessment of treatment response. Follow-up visits at 4 weeks (dose titration), 8 weeks, and 12 weeks are reasonable, with subsequent 3-monthly monitoring for long-term users. Patients should be educated about the expected timeline for response (often 4–8 weeks), the most common adverse effects (vivid dreams), and the absolute contraindication against concurrent opioid use.

7.4 Compounding and Cost

A practical challenge to LDN's broader clinical adoption is the requirement for compounding pharmacy preparation in most countries, as commercially manufactured LDN tablets are not available. Compounded LDN is typically not covered by insurance, with out-of-pocket costs ranging approximately $20–$100 per month — a significant financial consideration for patients with chronic conditions requiring long-term therapy. The lack of commercial support has also historically impeded the funding of large-scale clinical trials. Ensuring the quality and dose accuracy of compounded preparations is an important consideration, as variability in compounding quality could contribute to inconsistent clinical outcomes.

8. ONGOING AND FUTURE RESEARCH

8.1 The INNOVA Trial

The most significant ongoing investigation is the INNOVA trial (INNOVative treatment for fIbroMyAlgia) — a prospective, single-site, randomized, double-blinded, placebo-controlled phase III trial conducted in Spain (NCT number available at ClinicalTrials.gov), with a planned enrollment of 120 patients with FMS (4 or higher pain on a 10-point NRS). Participants are randomized 1:1 to LDN 4.5 mg/day or matched placebo, with a 1-year follow-up. The INNOVA trial represents several methodological advances over prior studies: (1) a substantially longer follow-up period enabling assessment of sustained efficacy; (2) incorporation of ecological momentary assessment (EMA) using mobile-technology-based real-time pain and symptom diaries, providing more ecologically valid and less recall-biased outcome data; (3) inclusion of MRI-based neuroimaging biomarkers to assess changes in brain metabolites related to neuroinflammation and central sensitization; (4) blood-based inflammatory biomarkers to explore LDN's in vivo immunomodulatory effects; and (5) cost-utility analysis. The INNOVA trial results are eagerly awaited and have the potential to substantially clarify LDN's efficacy, mechanisms, and cost-effectiveness in FMS.

8.2 Biomarker-Driven Patient Stratification

A critical gap in current LDN research is the absence of validated predictive biomarkers to identify a priori which FMS patients are most likely to respond. Given that meta-analyses consistently demonstrate significant but heterogeneous treatment effects, it is plausible that LDN is highly effective in a biologically defined FMS subpopulation (perhaps those with predominantly neuroinflammatory drivers, evidence of microglial activation, or specific opioid receptor gene polymorphisms) while being ineffective in others. Future trials incorporating neuroimaging (PET-based microglial activation imaging using TSPO ligands), quantitative sensory testing profiles, cytokine panels, and pharmacogenomic analyses will be essential for developing personalized treatment algorithms.

8.3 Combination Strategies

The combinatorial use of LDN with other modalities targeting FMS pathophysiology — non-opioid adjuvant analgesics, transcranial direct current stimulation (as evaluated by Paula et al.), cognitive behavioral therapy, aerobic exercise, and mindfulness-based interventions — warrants systematic investigation. Given the multidimensional pathophysiology of FMS, synergistic multimodal strategies that simultaneously address central sensitization, neuroinflammation, psychological comorbidity, and peripheral sensitization are most likely to achieve clinically meaningful and durable outcomes.

8.4 Expanding Populations

Current LDN trials in FMS have enrolled predominantly or exclusively women, reflecting the epidemiological predominance of FMS in females but creating a significant evidence gap for male patients and diverse ethnic groups. The neurobiological differences in pain processing and immune function between sexes may result in differential LDN responses, warranting dedicated investigation. Similarly, pediatric and adolescent FMS — though rare — represents an important population in which evidence for LDN is entirely absent.

9. DISCUSSION

The accumulated evidence for LDN in FMS presents a nuanced but ultimately encouraging picture. Taken in totality, the clinical literature supports the following conclusions: LDN significantly reduces pain compared to placebo with effect sizes (SMD ~0.6–0.9) that are clinically meaningful and at minimum comparable to approved agents; LDN produces consistent improvements in cognitive function, fatigue, and quality of life; the safety profile of LDN is distinctly favorable relative to all existing FMS pharmacotherapies; and the mechanistic rationale for LDN in FMS — targeting the neuroinflammatory and opioidergic pathophysiological substrates of central sensitization — is well-grounded in contemporary understanding of FMS biology.

The negative primary endpoint of the FINAL trial deserves careful contextual interpretation. A null result in a group-level primary analysis does not negate the signal of meaningful clinical benefit in a substantial responder subpopulation (45% achieving ≥30% pain reduction). In a heterogeneous condition such as FMS — where diverse pathophysiological subtypes likely coexist — group-level analyses inherently dilute subgroup-specific treatment effects. The co-primary finding of cognitive improvement in the FINAL trial reinforces LDN's biological plausibility in FMS and suggests that its effects may extend meaningfully beyond pain per se.

The comparative efficacy of LDN relative to approved FMS pharmacotherapies deserves mention. Effect sizes from the LDN meta-analyses (SMD −0.61 to −0.87) are numerically comparable or superior to those reported for duloxetine and pregabalin in FMS RCTs. LDN is substantially cheaper, has a more favorable adverse effect profile (particularly regarding weight gain, sedation, cognitive blunting, and cardiovascular effects — all concerns with approved agents), and lacks abuse/dependence potential — attributes of particular relevance given FMS's chronicity. However, direct head-to-head comparative trials between LDN and approved agents are entirely lacking and represent an important gap in the evidence base.

From a clinical practice perspective, LDN occupies a rational niche as an adjunctive or alternative option in the FMS treatment algorithm for patients who have inadequately responded to, or are intolerant of, first- and second-line therapies. The off-label status of LDN, requirement for compounding, variable insurance coverage, and the current low-to-moderate certainty of clinical evidence are legitimate barriers to broader adoption that must be transparently communicated to patients in shared decision-making discussions.

10. CONCLUSION

Low-dose naltrexone represents a mechanistically rational, evidence-supported, and favorably safe pharmacological option for the management of fibromyalgia syndrome. The dual mechanism of TLR4 antagonism on microglia (attenuating neuroinflammation) and compensatory upregulation of endogenous opioid tone (enhancing descending pain inhibition) directly targets the key pathophysiological substrates of FMS — substrates that are substantially unaddressed by currently approved pharmacotherapies. The evolving clinical evidence, anchored by five RCTs and confirmed by multiple 2024–2025 meta-analyses demonstrating significant pain reduction with favorable safety, provides a foundation for measured clinical adoption of LDN in appropriately selected FMS patients.

The primary outstanding limitation of the current evidence base is the small number of trials and modest aggregate sample sizes, which limit the statistical power to detect modest treatment effects and preclude robust subgroup analyses. The INNOVA phase III trial, with its 1-year follow-up, neurobiological substudies, and incorporation of modern outcomes methodology, will be a pivotal contribution to resolving current evidence uncertainties.

We recommend that clinicians consider LDN as a component of individualized, multimodal FMS treatment plans — particularly for patients with prominent cognitive dysfunction, fatigue, and neuroinflammatory features; those with inadequate response to standard therapies; or those intolerant of existing pharmacological options. Transparent patient communication regarding the off-label status, compounding requirements, and current evidence certainty is essential. Future research must prioritize biomarker-guided patient stratification, direct comparative effectiveness studies against approved agents, head-to-head trials in diverse demographic groups, and mechanistic neuroimaging investigations to fully realize LDN's therapeutic potential in this disabling condition.

Table 1. Summary of Key Randomized Controlled Trials of Low-Dose Naltrexone in Fibromyalgia Syndrome

Study (Year)	Design	N	Dose	Duration	Primary Outcome	Key Findings
Younger & Mackey (2009)	Single-blind, crossover pilot	10 F	4.5 mg/day	8 weeks (active)	Daily pain NRS	~30% pain reduction vs 2% with placebo; well tolerated
Younger et al. (2013)	RCT, crossover, double-blind	31 F	4.5 mg/day	12 weeks	Daily pain NRS	28.8% vs 18% pain reduction (p < 0.05); improved fatigue and QoL
Due Bruun et al. (2023)	RCT, crossover, double-blind	52 (46F, 6M)	4.5 mg/day	12 weeks per arm	Daily pain NRS	No significant difference vs placebo; study underpowered (target not reached)
FINAL Trial (Due Bruun et al., 2024)	RCT, parallel-group, double-blind	99 F	6 mg/day	12 weeks	Mean pain NRS	Primary outcome not significant (MD −0.34, p = 0.27); responder rate higher (45% vs 28% placebo); improved memory
Paula et al. (2023)	RCT, parallel-group, double-blind	~60	4.5 mg/day	5 weeks	Pain & QoL	Combination of LDN + tDCS superior to monotherapy and placebo

Abbreviations: RCT, randomized controlled trial; DB, double-blind; F, female; M, male; NRS, numerical rating scale; QoL, quality of life; tDCS, transcranial direct current stimulation.

 Table 2. Summary of Key Systematic Reviews and Meta-Analyses of LDN in Fibromyalgia (2023–2025)

Authors (Year)	Journal	RCTs Included	Key Findings	Certainty of Evidence
Vatvani et al. (2024)	Korean J Pain	5	SMD −0.61 (primary); −0.87 (sensitivity). Trial sequential analysis confirmed benefit (boundary crossed).	Low-to-moderate (small RCTs)
Rizwan et al. (2025)	Ann Med Surg	5	SMD −0.61 (primary); −0.87 (sensitivity). Superiority not confirmed in responder analysis.	Low-to-moderate
Rizwan et al. (2025)	ACR Convergence	5 RCTs (through Dec 2024)	SMD −0.851; functional outcomes improved; increased vivid dreams (OR 2.17).	Low-to-moderate
Meta-analysis (2025)	J Pain Palliat Care Pharmacother	8 studies	Within-group: SMD −1.03 (pain), −1.02 (severity); between-group differences not significant due to high heterogeneity (I²).	Very low to low
Yang et al. (2023)	J Pain Res (Mayo Clinic)	Systematic review	Consistent safety signal; improvement in pain and QoL; no serious adverse events reported.	Low

Abbreviations: SMD, standardized mean difference; TSA, trial sequential analysis; RCT, randomized controlled trial; AE, adverse event; ACR, American College of Rheumatology; QoL, quality of life.

REFERENCES

1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–610.

2. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–1555.

3. Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645–660.

4. Di Carlo M, Bianchi B, Salaffi F, et al. Fibromyalgia: one year in review 2024. Clin Exp Rheumatol. 2024;42(6):1141–1149.

5. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672.

6. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538.

7. Due Bruun K, Christensen R, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Bye-Møller L, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31–e39.

8. Due Bruun K, Amris K, Vaegter HB, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023;8(1):e1088.

9. Paula TMH, Castro MS, Medeiros LF, et al. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial. Braz J Anesthesiol. 2023;73(4):409–417.

10. Vatvani AD, Patel P, Hariyanto TI, Yanto TA. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain. 2024;37(4):367–378.

11. Rizwan R, Grewal S, Banda S, Hazique M. Efficacy and safety of low-dose naltrexone in fibromyalgia: an updated systematic review and meta-analysis of randomized controlled trials (RCTs). Ann Med Surg. 2025;87(5):2928–2935.

12. Rizwan R, Grewal S, Banda S, Hazique M. Efficacy and safety of low-dose naltrexone in fibromyalgia: an updated systematic review and meta-analysis of RCTs. Abstract 1245. Presented at: ACR Convergence 2025; October 24–29, 2025; Chicago, IL.

13. Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review. J Pain Res. 2023;16:1017–1023.

14. Efficacy of low-dose naltrexone in treating patients with fibromyalgia: systematic review and meta-analysis. J Pain Palliat Care Pharmacother. 2025;39(3):363–373. doi:10.1080/15360288.2025.2496526

15. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459.

16. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci. 2018;6(4):82.

17. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83–95.

18. Kučić N, Rački V, Šverko R, et al. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci. 2021;22(16):8429.

19. Driver CN, D'Souza RS. Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis. Biomedicines. 2023;11(4):1087.

20. Bruun KD, Jensen HI, Blichfeldt-Eckhardt MR, et al. Performance of the 2016 diagnostic criteria for fibromyalgia in a tertiary care pain rehabilitation setting: a diagnostic accuracy study. Heliyon. 2023;9:e15638.

21. Moser T, et al. Low-dose naltrexone for severe fibromyalgia syndrome: a report of a case with two-year follow-up. Cureus. 2025;17(5):e83824.

22. Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open. 2022;12(1):e055351.

23. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388–2395.

24. Clauw DJ, D'Arcy Y, Gebke K, et al. Normalizing fibromyalgia as a chronic illness. Postgrad Med. 2018;130(1):9–18.

25. Atta AA, Ibrahim WW, Mohamed AF, Abdelkader NF. Microglia polarization in nociplastic pain: mechanisms and perspectives. Inflammopharmacology. 2023;31(3):1053–1067.

26. Aalto H, et al. Real-world effectiveness and tolerability of low-dose naltrexone to treat chronic pain: a retrospective cohort study of one pain physician's practice. J Pain Res. 2025. doi:10.2147/JPR.S500000.

27. Chou R, et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Ann Intern Med. 2015;162(4):276–286.

28. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–328.